A Phase 3 Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Orally Administered NNZ-2591 in Pediatric Participants with Phelan McDermid Syndrome NEU-2591-PMS-302
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Orally Administered NNZ-2591 Compared with Placebo in Pediatric Participants with Phelan McDermid Syndrome (The KOALA Study)
